Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo-Reference-Cited by-同舟云学术

Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo

Published:2022-02-02 Issue:6 Volume:119 Page:
ISSN:0027-8424
Container-title:Proceedings of the National Academy of Sciences
language:en
Short-container-title:Proc. Natl. Acad. Sci. U.S.A.

Author:

Hoff Nicole A.¹^ORCID,Bratcher Anna¹^ORCID,Kelly J. Daniel²³⁴,Musene Kamy⁵,Kompany Jean Paul⁵,Kabamba Michel⁶^ORCID,Mbala-Kingebeni Placide⁵,Dighero-Kemp Bonnie⁷,Kocher Gregory⁷,Elliott Elizabeth⁷,Reilly Cavan⁸,Halbrook Megan¹,Ilunga Kebela Benoit⁹,Gadoth Adva¹^ORCID,Ngoie Mwamba Guillaume⁶,Tambu Merly⁵,McIlwain David R.¹⁰,Mukadi Patrick⁵^ORCID,Hensley Lisa E.⁷^ORCID,Ahuka-Mundeke Steve⁵,Rutherford George W.²³^ORCID,Muyembe-Tamfum Jean Jacques⁵,Rimoin Anne W.¹^ORCID

Affiliation:

1. Department of Epidemiology, University of California, Los Angeles, CA 90095

2. Department of Epidemiology and Biostatistics, University of California, San Francisco, CA 94158

3. Institute for Global Health Sciences, University of California, San Francisco, CA 94158

4. F.I. Proctor Foundation, University of California, San Francisco, CA 94143

5. Department of Epidemiology, National Institute of Biomedical Research, Kinshasa, Democratic Republic of the Congo

6. Expanded Programme for Immunization, Kinshasa, Democratic Republic of the Congo

7. Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21701

8. Division of Biostatistics, University of Minnesota, Minneapolis, MN 55455

9. Division of Disease Control, Ministry of Health, Kinshasa, Democratic Republic of Congo

10. Department of Pathology, Stanford University, Stanford, CA 94304

Abstract

Significance This paper describes findings from a seroepidemiologic study involving a cohort of Ebola-vaccinated individuals from North Kivu, Democratic Republic of the Congo (DRC), who were studied as part of a collaborative effort between American and Congolese scientists and epidemiologists. Our study examines antibody response at 21 d and 6 mo postvaccination after single-dose rVSVΔG-ZEBOV-GP vaccination among Ebola virus disease–exposed and potentially exposed populations in the DRC. At 21 d of follow-up, 87.2% had an antibody response. Additionally, 95.6% demonstrated antibody persistence at 6 mo of follow-up. These findings give crucial evidence that antibody response and persistence after Ebola vaccination is robust in outbreak settings in the DRC, knowledge that significantly informs the use of vaccination for outbreak control.

Funder

Bill and Melinda Gates Foundation

HHS | NIH | National Institute of Allergy and Infectious Diseases

Division of Intramural Research, National Institute of Allergy and Infectious Diseases

Publisher

Proceedings of the National Academy of Sciences

Subject

Multidisciplinary

Link

https://pnas.org/doi/pdf/10.1073/pnas.2118895119

Reference43 articles.

1. Ebola virus vaccine receives prequalification

2. Emergency Ebola response: a new approach to the rapid design and development of vaccines against emerging diseases

3. European Medicines Agency First vaccine to protect against Ebola. European Medicines Agency. https://www.ema.europa.eu/en/news/first-vaccine-protect-against-ebola. Accessed 9 June 2021.

4. U.S. Food and Drug Administration First FDA-approved vaccine for the prevention of Ebola virus disease marking a critical milestone in public health preparedness and response. FDA. https://www.fda.gov/news-events/press-announcements/first-fda-approved-vaccine-prevention-ebola-virus-disease-marking-critical-milestone-public-health. Accessed 9 June 2021.

5. Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing the real-world effectiveness of the rVSV-ZEBOV vaccine;The Lancet Infectious Diseases;2024-08

2. 2020 Ebola virus disease outbreak in Équateur Province, Democratic Republic of the Congo: a retrospective genomic characterisation;The Lancet Microbe;2024-02

3. Prevention and post-exposure management of occupational exposure to Ebola virus;The Lancet Infectious Diseases;2024-02

4. Vaccines to prevent Ebola virus disease: current challenges and perspectives;Problems of Virology;2023-11-07

5. Ebola virus disease in children: epidemiology, pathogenesis, management, and prevention;Pediatric Research;2023-10-30